|
🐬
|
Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy
N. Chirmule,
V. Jawa,
B. Meibohm
|
8 |
2012 |
8
🐬
|
|
🦁
|
T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation.
V. Jawa,
L. Cousens,
M. Awwad,
E. Wakshull,
H. Kropshofer,
Anne Searls De Groot
|
7 |
2013 |
7
🦁
|
|
🐢
|
Highly Aggregated Antibody Therapeutics Can Enhance the in Vitro Innate and Late-stage T-cell Immune Responses
11 auth.
M. Joubert,
M. Hokom,
Catherine Eakin,
Lei Zhou,
M. Deshpande,
M. Baker,
...
T. Goletz,
Bruce A. Kerwin,
Naren Chirmule,
L. Narhi,
V. Jawa
|
7 |
2012 |
7
🐢
|
|
🐜
|
Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein.
12 auth.
E. Koren,
A. Groot,
V. Jawa,
K. Beck,
T. Boone,
Daniel G Rivera,
...
L. Li,
D. Mytych,
M. Koscec,
D. Weeraratne,
S. Swanson,
W. Martin
|
7 |
2007 |
7
🐜
|
|
🐢
|
Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics
14 auth.
M. Joubert,
M. Deshpande,
Jane Yang,
Helen Reynolds,
Christine J. Bryson,
M. Fogg,
M. Baker,
Jonathan Herskovitz,
T. Goletz,
Lei Zhou,
...
M. Moxness,
G. C. Flynn,
L. Narhi,
V. Jawa
|
6 |
2016 |
6
🐢
|
|
🦁
|
T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020
7 auth.
V. Jawa,
Frances E Terry,
J. Gokemeijer,
S. Mitra-Kaushik,
Brian J. Roberts,
S. Tourdot,
...
Anne Searls De Groot
|
6 |
2020 |
6
🦁
|
|
🐜
|
Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges.
9 auth.
W. Jiskoot,
G. Kijanka,
T. Randolph,
J. Carpenter,
Atanas V. Koulov,
Hanns-Christian Mahler,
...
M. Joubert,
V. Jawa,
L. Narhi
|
6 |
2016 |
6
🐜
|
|
🐢
|
Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics.
8 auth.
Danika Wullner,
Lei Zhou,
Eric Bramhall,
Andrew J Kuck,
T. Goletz,
S. Swanson,
...
N. Chirmule,
V. Jawa
|
6 |
2010 |
6
🐢
|
|
🐜
|
Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies.
9 auth.
M. Moxness,
Suzanna M Tatarewicz,
D. Weeraratne,
N. Murakami,
Danika Wullner,
D. Mytych,
...
V. Jawa,
E. Koren,
S. Swanson
|
6 |
2005 |
6
🐜
|
|
🦁
|
Evaluating Immunogenicity Risk Due to Host Cell Protein Impurities in Antibody-Based Biotherapeutics
7 auth.
V. Jawa,
M. Joubert,
Qingchun Zhang,
M. Deshpande,
Suminda Hapuarachchi,
Michael P. Hall,
...
G. C. Flynn
|
6 |
2016 |
6
🦁
|
